Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Smoking Reduction on Endothelial Glucocalyx and Arterial Wall Properites During Medically-aided Smoking Cessation Program

Next Previous
Trial Profile

Effect of Smoking Reduction on Endothelial Glucocalyx and Arterial Wall Properites During Medically-aided Smoking Cessation Program

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varenicline (Primary) ; Nicotine; Nicotine
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Acronyms SMOKING-VAR-NIC-ATTIKON

Most Recent Events

  • 01 Apr 2020 Planned number of patients changed from 100 to 600.
  • 01 Apr 2020 Planned End Date changed from 1 Feb 2015 to 1 Dec 2020.
  • 01 Apr 2020 Planned primary completion date changed from 1 Feb 2015 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top